title: New-onset heart failure in association with severe hypertension during trastuzumab therapy.
abstract: Heart failure is a dreaded complication of trastuzumab therapy in women with breast cancer overexpressing the human epidermal growth factor receptor (HER)-2. Experimental studies have pointed out that the HER-2 signaling pathway is important in the adaptation to high afterload conditions and its inactivation leads to cardiac decompensation. Herein, we report on 2 patients with breast cancer who were receiving trastuzumab monotherapy and required hospital admission for new-onset heart failure. This occurred at a time of unprecedented blood pressure elevations, in one case due to cessation of antihypertensive medications and in the other case due to a scleroderma crisis. Although trastuzumab may not have been the precipitating factor for blood pressure dyscontrol in these patients, severe, uncontrolled hypertension may have been the precipitating factor for trastuzumab-related acute heart failure. These 2 cases add to previous reports recognizing systemic hypertension as a risk factor for the development of trastuzumab cardiotoxicity and translate experimental observations of the significance of the HER-2 signaling pathway to the bedside. Pending further confirmation, the present observations may raise awareness of the need for appropriate monitoring and control of systemic hypertension in patients receiving trastuzumab, or potentially any other HER-2-targeted therapy.
authors.affiliation: Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: herrmann.joerg@mayo.edu.
authors.forename: Joerg
authors.initials: J
authors.lastname: Herrmann
authors.affiliation: Department of Medicine, Mayo Clinic, Rochester, MN.
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Herrmann
authors.affiliation: Department of Oncology, Mayo Clinic, Rochester, MN.
authors.forename: Tufia C
authors.initials: TC
authors.lastname: Haddad
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D008875:Middle Aged; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab